Eton Pharma Reports Positive Results From Bioequivalence Study Of ET-600 - Quick Facts

(RTTNews) - Eton Pharmaceuticals (ETON) announced positive results from bioequivalence study of ET-600, a patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. In a bioequivalence study conducted in 75 human subjects, ET-600 showed pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient.

"We expect to submit the NDA shortly and have begun pre-launch commercial readiness activities in anticipation of a potential launch in the first quarter of 2026," said Sean Brynjelsen, CEO of Eton Pharmaceuticals.

For More Such Health News, visit rttnews.com.